Company / Capital Expenditures
ENDRA Life Sciences Inc. Capital Expenditures History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$75.3K
FY2020
5-year range
$7.9K / $100.0K
FY2017-FY2020
Trend
-24.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $7,862 to $75,333 over the past 2 years.
Based on SEC 10-K filings.
$75,333 in FY2020 with a 3-year CAGR of +112.4%.
Improved from $7,862 to $75,333 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +112.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +112.4%, indicating consistent growth.
- In FY2020, capital expenditures decreased 24.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $75.3K | -24.7% |
| FY2019 | $100.0K | +1171.9% |
| FY2018 | $7.9K | +0.0% |
| FY2017 | $7.9K | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026